Neutrophil count appears to be an independent prognostic factor for overall mortality in patients with localized prostate cancer, a new study published in the journal BMC Cancer has shown.

For the study, researchers from Centre Hospitalier de l’Université de Montréal in Montreal, Canada, sought to investigate the impact of systemic inflammation markers like leukocyte count and metabolic comorbidities on overall survival in patients with localized prostate cancer who have undergone radiotherapy.

Researchers rertrospectively analyzed data from 1,772 patients with localized prostate cancer treated with definitive external beam radiotherapy or brachytherapy. Of those, 950 had available blood count data.

The study demonstrated that neutrophil count (P=0.04), cardiac history (P=0.008), age (P=0.001), and Cancer of the Prostate Risk Assessment (CAPRA) score (P=0.0002) were associated with mortality on univariate analysis.


Continue Reading

RELATED: Early Docetaxel With ADT Improves Survival in Metastatic Prostate Cancer

Results showed that on multivariate analysis, neutrophil count (HR = 1.18; 95% CI, 1.017, 1.37; P=0.028), age (HR = 1.06; 95% CI, 1.01, 1.1; P=0.008) and Cancer of the Prostate Risk Assessment (CAPRA) score (HR = 1.16, 95% CI, 1.03, 1.31; P=0.015) were independent predictors of overall survival.

The authors concluded that a validation cohort is necessary to confirm these findings.

Reference

  1. Bahig H, Taussky D, Delouya G, et al. Neutrophil count is associated with survival in localized prostate cancer. BMC Cancer. 2015;15:594.